ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1779

A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis

Li Alemo Munters1,2, Ingela M. Loell3, Joan Raouf4, Maryam Dastmalchi3, Eva Lindroos5, Christina Ottosson6, Yi-Wen Chen7, Annemarie F van Delden8, Mona Esbjörnsson9, Marina Korotkova10, Helene Alexanderson11, Kanneboyina Nagaraju12 and Ingrid E. Lundberg13, 1Department of Medicine, Rheumatology Unit, , Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 2Department of Physiotherapy, Rheumatology Unit, Karolinska University Hospital in Solna, Stockholm, Sweden, Stockholm, Sweden, 3Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 5Department of Medicine, Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 6Department of Medicine, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 7Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, USA., Washington DC, DC, 8Department of Medicine,, Rheumatology Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, 9Department of Physiology, Karolinska Institutet, Huddinge, Sweden, 10Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, 11Department of Neurobiology, Care Science and Society, Division of Physiotherapy, Division of Physiotherapy, Karolinska Institutet, Huddinge, Stockholm, Sweden, 12Research Center for Genetic Medicine, Children’s National Medical Center, Washington DC, DC, 13Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disability, Disease Activity, exercise and polymyositis/dermatomyositis (PM/DM), Gene Expression

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose:

This pilot study is a hypothesis-driven exploratory part of a larger randomized controlled trial evaluating effects of a supervised 12-week endurance exercise program (EG) compared to a non-interventional control group (CG) in patients with established polymyositis (PM) and dermatomyositis (DM). The aim was to determine the potential mechanisms underlying the beneficial effects of endurance exercise.

Methods:

A subgroup of 15 patients with paired baseline and 12 week follow-up muscle biopsies (EG n=7 and CG n=8) were included in the analysis. mRNA expression profiling and immunohistochemistry analysis of biopsies from vastus lateralis muscle were used to determine molecular changes associated with the changes in clinical assessments. Clinical assessments consisted of: Maximal oxygen uptake (VO2 max) and cycling time to exhaustion at 65% of VO2 max. Lactate levels in the vastus lateralis muscle were measured with microdialysis directly after the cycling. Clinical disease activity was assessed according to the International Myositis Assessment and Clinical Studies Group (IMACS) criteria.

Results:

Patients in the EG clinically improved compared to the CG in cycling time (p<0.01) and VO2 max (p<0.05), whereas lactate levels at exhaustion were decreased or unchanged. A majority of the patients in the EG were responders with reduced disease activity compared to the CG (p<0.05). These clinical changes were accompanied with down-regulation in genes related to inflammation and ER-stress , such as Eukaryotic translation initiation factor 2C, 4 (-2.6, p<0.01) and Cell adhesion molecule with homology to L1CAM (-1.6, p<0.01); and up-regulation in genes related to capillary growth, cytoskeletal remodeling, muscle hypertrophy, mitochondria biogenesis and protein synthesis, such as Toll-like receptor 7 (1.7 fold, p<0.01), Fms-related tyrosine kinase 3 ligand (4.3 fold, p<0.01), Insulin-like growth factor 1 receptor (1.4, p<0.001), Insulin receptor (1.3, p<0.001). The CG displayed non- synchronized regulation of genes, although up-regulation in genes related to type 1 interferon and apoptosis was determined. No significant changes were displayed in the number of T-cells and macrophages in the EG nor in the CG.  The EG but not the CG showed a higher number of capillaries per mm2 in the follow up biopsy.

Conclusion:

Our data showed that endurance exercise in patients with PM and DM may induce genes involved in muscle growth and remodeling as previously reported in healthy individuals. In addition, the exercise suppressed inflammation and ER-stress accompanied with reduced clinical disease activity in the patients. The findings suggest that endurance exercise may be beneficial by activating the muscle growth program which overwrites the muscle atrophy process, and suppressing the inflammation responses in parallel in the patients’ muscles.


Disclosure:

L. Alemo Munters,
None;

I. M. Loell,
None;

J. Raouf,
None;

M. Dastmalchi,
None;

E. Lindroos,
None;

C. Ottosson,
None;

Y. W. Chen,
None;

A. F van Delden,
None;

M. Esbjörnsson,
None;

M. Korotkova,
None;

H. Alexanderson,
None;

K. Nagaraju,
None;

I. E. Lundberg,

BMS,

2,

Novartis Pharmaceutical Corporation,

5.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-controlled-clinical-histological-and-mrna-profiling-pilot-study-of-endurance-exercise-in-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology